Evidence map›Paper›PMID 28278081›Full record

ArticleCancer biology & therapy2017

Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.

Xun Cai, Chuan Tian, Liwei Wang, Rongyuan Zhuang, Xiaowei Zhang, Yuanbiao Guo, Hongmin Lu, Hui Wang, Xiaoyu Li, Junwei Gao and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. [Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Xun Caia Department of Oncology , Shanghai General Hospital, Nanjing Medical University , Shanghai , China.
Chuan Tianc Department of Nuclear Medicine , People's Hospital of Guizhou Province , Guiyang , China.
Liwei Wanga Department of Oncology , Shanghai General Hospital, Nanjing Medical University , Shanghai , China.
Rongyuan Zhuangd Department of Oncology , Zhongshan Hospital, Shanghai Medical College, Fudan University , Shanghai , China.
Xiaowei Zhange Department of Medical Oncology , Shanghai Cancer Center, Shanghai Medical College, Fudan University , Shanghai , China.
Yuanbiao Guof Department of Traditional Chinese Medicine , Ruijin Hospital, Medical College, Shanghai Jiaotong University , Shanghai , China.
Hongmin Lug Department of Oncology , Renji Hospital, Medical College, Shanghai Jiaotong University , Shanghai , China.
Hui Wangh Department of Oncology , Shanghai Tenth People's Hospital, Shanghai Tongji University , Shanghai , China.
Xiaoyu Lii Department of Clinical Pharmacy , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Junwei Gaoi Department of Clinical Pharmacy , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Qi Lia Department of Oncology , Shanghai General Hospital, Nanjing Medical University , Shanghai , China.
Chungang Wangj Department of Radiotherapy , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Shanghai First People's Hospital · CNShanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNGuizhou Provincial People's Hospital · CNRenji Hospital · CNRuijin Hospital · CNTongji University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It remains uncertain whether there is an correlation between clinical pharmacokinetic parameters and outcomes for metastatic colorectal cancer especially with UGT1A1 *28 and *6 wild type (*1/*1-*1/*1) for serious events associated with Irinotecan are largely excluded. This study retrospectively analyzed the relationship between Irinotecan metabolite levels and outcomes of UGT1A1 *1/*1-*1/*1 genotype arrangement. Blood samples (n = 244) were collected for analysis of plasma DPD activity (before first chemotherapy) and SN-38 levels (1.5 and 49 hour after CPT-11 administration). Clinical variables such as toxicity and outcomes were then assessed. Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the C

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinColorectal NeoplasmsDihydrouracil Dehydrogenase (NADP)FemaleFluorouracilGlucuronosyltransferaseHumansIrinotecanLeucovorinMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesCamptothecinDihydrouracil Dehydrogenase (NADP)FluorouracilGlucuronosyltransferaseIrinotecanLeucovorinUGT1A1 EnzymeColonic neoplasmdihydropyrimidine dehydrogenasedrug metabolismgenetic polymorphismIrinotecanrate-limiting enzymeuridine diphosphate glucuronosyltransferase

Identifiers

PMID28278081
PMCPMC5389420
OpenAlexW2588339066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.